Free tool
FAERS Monitor: Delstrigo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210807 or its brand name (Delstrigo, Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate). Reports on generic versions are filed under their own applications.
Reports
313
Serious
259
83% of reports
Hospitalization
71
Death reported
24
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death20
- nausea20
- weight increased18
- pain17
- anxiety14
- fatigue13
- no adverse event13
- pathogen resistance13
- depression12
- headache12
- product dose omission issue12
- diarrhoea11
- virologic failure11
- emotional distress10
- weight decreased10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2019 | 6 |
| 2020 | 25 |
| 2021 | 33 |
| 2022 | 32 |
| 2023 | 67 |
| 2024 | 64 |
| 2025 | 54 |
| 2026 | 31 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,846 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| virologic failureSignal | 11 | 137.7 | 77.0 | 1,357 |
| pathogen resistanceSignal | 13 | 96.0 | 56.3 | 1,128 |
| emotional distressSignal | 10 | 5.6 | 3.0 | 33 |
| weight increasedSignal | 18 | 5.4 | 3.4 | 61 |
| no adverse eventSignal | 13 | 4.8 | 2.8 | 36 |
| depressionSignal | 12 | 3.5 | 2.0 | 20 |
| anxietySignal | 14 | 3.3 | 2.0 | 21 |
| product dose omission issueSignal | 12 | 2.7 | 1.6 | 12 |
| weight decreasedSignal | 10 | 2.4 | 1.3 | 7 |
| pain | 17 | 1.9 | 1.2 | 6 |
| nausea | 20 | 1.7 | 1.1 | 5 |
| death | 20 | 1.6 | 1.0 | 4 |
| headache | 12 | 1.3 | 0.7 | 1 |
| diarrhoea | 11 | 1.1 | 0.6 | 0 |
| fatigue | 13 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.